The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets

Clinical and Translational Oncology

Volumn 16, Issue 11, 2014, Pages 937-941

  Ramon y Cajal, S ^a,b   De Mattos Arruda, L ^a,b   Sonenberg, N ^c   Cortes, J ^a,d   Peg, V ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c MCGILL UNIVERSITY   (Canada)

^d Medica Scientia Innovation Research (MedSIR)   (Spain)

Author keywords

Breast cancer; Intra tumor heterogeneity; Proteomics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR PROTEIN; EIF4EBP1 PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

BREAST CANCER; BREAST METASTASIS; CANCER RESISTANCE; CANCER THERAPY; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; INTRA TUMOR HETEROGENEITY; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; ANIMAL; BREAST TUMOR; FEMALE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BREAST NEOPLASMS; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 84919844789     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1203-9     Document Type: Review

References (14)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
2. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012;13(4):e178–85.
3. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intra-tumor heterogeneity and branched evolution revealed by multi region sequencing. N Engl J Med. 2012;366(10):883–92.
4. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9.
5. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72(19):4875–82.
6. Newburger DE, Kashef-Haghighi D, Weng Z, Salari R, Sweeney RT, Brunner AL, et al. Genome evolution during progression to breast cancer. Genome Res. 2013;23(7):1097–108.
7. De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol. 2013;10(7):377–89.
8. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4.
9. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell. 2012;149(5):994–1007.
10. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13(6):224.
11. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.
12. Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, Sabadell MD, et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res. 2007;13(1):81–9.
13. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, et al. 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res. 2007;67(16):7551–5.
14. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 2012;72(24):6468–76.